KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cancer | Synapse
March 16, 2026Open Access
KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cancer
Puntos clave
The research investigates how KAT2B influences RAD51C to affect sensitivity to olaparib in colorectal cancer.
Analyzed the role of KAT2B in colorectal cancer cells using genetic and biochemical assays.
Examined the effects of RAD51C mutations on olaparib resistance in vitro.
Utilized cellular models to assess sensitivity to olaparib under different genetic modifications.
KAT2B suppression was found to enhance sensitivity to olaparib in colorectal cancer cells.
RAD51C reversion mutations were linked to increased resistance to olaparib therapy.
Combination approaches may improve treatment outcomes for patients resistant to olaparib.
Resumen
These results offer vital and novel insights into the combination of inhibitors in patients who are resistant to olaparib therapy, especially patients with RAD51C reversion mutations.